Efficacy and safety of cyclophosphamide treatment in progressive multiple sclerosis;Efficacité et tolérance du cyclophosphamide dans le traitement de fond des formes progressives de la sclérose en plaques

Revue Neurologique

Volumn 165, Issue 12, 2009, Pages 1086-1091

  Ait Ben Haddou, E ^a   Benomar, A ^a,b   Ahid, S ^b   Chatri, H ^a   Slimani, C ^a   Hassani, M ^a   El Alaoui Taoussi, K ^a,b   Abouqal, R ^b   Yahyaoui, M ^a  

^a IBN SINA HOSPITAL   (Morocco)

^b MOHAMMED V UNIVERSITY   (Morocco)

Author keywords

Cyclophosphamide; Formes progressives; Scl rose en plaques

Indexed keywords

CYCLOPHOSPHAMIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; RETROSPECTIVE STUDY; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGE OF ONSET; ANTIRHEUMATIC AGENTS; CYCLOPHOSPHAMIDE; DISABLED PERSONS; DISEASE PROGRESSION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RETROSPECTIVE STUDIES; SAFETY; YOUNG ADULT;

EID: 71349084756     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurol.2009.03.013     Document Type: Article

References (36)

1. Aimard G., Girard P.F., and Raveau J. Multiple sclerosis and the autoimmunization process. Treatment by antimitotics (Lyon) 215 (1966) 345-352
2. Appenzeller S., Blatyta P.F., and Costallat L.T. Ovarian failure in SLE patients using pulse cyclophosphamide: comparison of different regimes. Rheumatol Int 28 (2008) 567-571
3. Delmont E., Chanalet S., Bourg V., Soriani M.H., Chatel M., and Lebrun C. Association CPM méthylprednisolone en traitement de fond des scléroses en plaques de type progressif : facteurs prédictifs d'une réponse clinique. Rev Neurol (Paris) 160 (2004) 659-665
4. Edan G., Milier D., Clanet M., et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: A randomised multicenter study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 62 (1997) 112-118
5. Gladstone D.E., Zamkoff K.W., Krupp L., et al. High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis. Arch Neurol 63 (2006) 1388-1393
6. Gladstone D.E., Golightly M.G., and Brannagan III T.H. High dose cyclophosphamide preferentially targets naïve T (CD45/CD4/RA+) cells in CIDP and MS patients. J Neuroimmunol 190 (2007) 121-126
7. Goodkin D.E., Plencner S., Palmer-Saxerud J., Teetzen M., and Hertsgaard D. Cyclophosphamide in chronic progressive multiple sclerosis. Maintenance vs nonmaintenance therapy. Arch Neurol 44 (1987) 823-827
8. Goodin D.S., Arnason B.G.W., Coyle P.K., Frhan E.M., and Paty D.W. The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis. Report of the therapeutics and technology Assessement subcommittee of the American Academy of Neurology. Neurology 61 (2003) 1332-1338
9. Hartung HP, Gonsette R, MIMS study Group. Mitoxantrone in progressive multiple sclerosis a placebo-controlled, randomized, observer-blind phase III trial: clinical results and three-year follow-up. Neurology 1999;52(2):290.
10. Hauser S.L., Dawson D.M., Lehrich J.R., et al. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 308 (1983) 173-180
11. Hommes OR, Aerts F, Bahr U, Schulten HR. Cyclophosphamide levels in serum and spinal fluid of multiple sclerosis patients treated with immunosuppression. J. Neurol Sci 1983;58:297-303.
12. Hohol M.J., Olek M.J., Orav E.J., et al. Treatment of progressive multiple sclerosis with pulse cyclophosphamide/methylprednisolone: Response to therapy is linked to the duration of progressive disease. Mult Scler 5 (1999) 403-409
13. Jacobs L.D., Cookfair D.L., Rudick R.A., et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39 (1996) 285-294
14. Jefery D.R., and Herndon R. Review of mitoxantrone in the treatment of multiple sclerosis. Neurology 63 (2004) 519-524
15. Koch M., Mostert J., Heersema D., and De Keyser J. Progression in multiple sclerosis: Further evidence of an age dependent process. J Neurol Sci 15 (2007) 35-41
16. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 33 (1983) 1444-1452
17. Lepage E., Leray E., Taurin G., Coustans M., Chaperon J., Morrissey S.P., and Edan G. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: Treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. J Neurol Neurosurg Psychiatry 79 (2008) 52-56
18. Likosy W.H., Fireman B., Elmore R., et al. Intense immunosuppression in chronic progressive multiple sclerosis: The Kaiser study. J Neurol Neurosurg Psychiatry (1991) 1055-1060
19. McDonald WI, Compston A, Edan G, et al. (2001). Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50(1):121-7.
20. Perini P, Marangoni S, Tzinteva E et al. (2001). Two years therapy of secondary progressive multiple sclerosis (SPMS) with pulse intravenous cyclophosphamide/methyprednisolone. Clinical and MRI data. Multiple sclera 2001;7:S62.
21. Neuhaus O., Kieseier B.C., and Hartung HP. Immunosuppressive agents in multiple sclerosis. Neurotherapeutics 4 (2007) 654-660
22. Paterson P.Y. Cyclophosphamide treatment of experimental allergic encephalomyelitis in Lewis rats. J Immunol 106 (1971) 1473-1479
23. Perini P., Calabrese M., and Tiberio M. Mitoxantrone versus CPM in secondary progressive multiple sclerosis: A comparative study. J Neurol 253 (2006) 1034-1040
24. Perini P., Calabrese M., Rinaldi L., and Gallo P. The safety profile of cyclophosphamide in multiple sclerosis therapy. Expert Opin Drug Saf 6 (2007) 183-190
25. Portaccio E., Zipoli V., Siracusa G., Piacentini S., Sorbi S., and Amato M.P. Safety and tolerability of cyclophosphamide "pulses" in multiple sclerosis: A prospective study in a clinical cohort. Mult Scler 9 (2003) 446-450
26. Poser C.M., Paty D.W., Scheinberg L., and Mc Donald W.I. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 13 (1983) 227-231
27. Prisms, and Prevention of relapses and disability by Interferon beta-1a subcutaneously in multiple sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 7 (1998) 1498-1504
28. Radis C.D., Kahl L.E., Baker G.L., et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis Rheum 38 (1995) 1120-1127
29. The Canadian cooperative Multiple Sclerosis Study Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 337 (1991) 441-446
30. The interferon Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Clinical results of a multicenter, randomized, double-blind, placebo controlled trial. Neurology 43 (1993) 655-661
31. Thompson A.J., Montalban X., Barkhof F., et al. Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol 47 (2000) 831-835
32. Weiner H.L., Mackin G.A., Orav E.J., et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: Final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 43 (1993) 910-918
33. Zéphir H., De Seze J., Sénéchal O., et al. Traitement des formes progressives de sclérose en plaques par le CPM. Rev Neurol (Paris) 158 (2002) 65-69
34. Zéphir H., De Seze J., Duhamel A., et al. Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients. J Neurolog Sci 15 218 (2004) 73-77
35. Zéphir H., De Sèze J., Dujardin K., et al. L'impact cognitif de la mitoxantrone et méthylprednisolone dans la sclérose en plaques : une étude ouverte. Rev Neurol (Paris) 164 (2008) 47-52
36. Zipoli V., Portaccio E., Hakiki B., Siracusa G., Sorbi S., and Pia Amato M. Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: An open-label comparative study of efficacy and safety. J Neurol Sci 26 (2008) 25-30